» Articles » PMID: 33233764

Short Disordered Epitope of CRTAM Ig-Like V Domain As a Potential Target for Blocking Antibodies

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2020 Nov 25
PMID 33233764
Authors
Affiliations
Soon will be listed here.
Abstract

Class-I Restricted T Cell-Associated Molecule (CRTAM) is a protein that is expressed after T cell activation. The interaction of CRTAM with its ligand, nectin-like 2 (Necl2), is required for the efficient production of IL-17, IL-22, and IFNγ by murine CD4 T cells, and it plays a role in optimal CD8 T and NK cell cytotoxicity. CRTAM promotes the pro-inflammatory cytokine profile; therefore, it may take part in the immunopathology of autoimmune diseases such as diabetes type 1 or colitis. Thus, antibodies that block the interaction between CRTAM and Necl2 would be useful for controlling the production of these inflammatory cytokines. In this work, using bioinformatics predictions, we identified three short disordered epitopes (sDE1-3) that are located in the Ig-like domains of murine CRTAM and are conserved in mammalian species. We performed a structural analysis by molecular dynamics simulations of sDE1 (QHPALKSSKY, Ig-like V), sDE2 (QRNGEKSVVK, Ig-like C1), and sDE3 (CSTERSKKPPPQI, Ig-like C1). sDE1, which is located within a loop of the contact interface of the heterotypic interaction with Nectl2, undergoes an order-disorder transition. On the contrary, even though sDE2 and sDE3 are flexible and also located within loops, they do not undergo order-disorder transitions. We evaluated the immunogenicity of sDE1 and sDE3 through the expression of these epitopes in chimeric L1 virus-like particles. We confirmed that sDE1 induces polyclonal antibodies that recognize the native folding of CRTAM expressed in activated murine CD4 T cells. In contrast, sDE3 induces polyclonal antibodies that recognize the recombinant protein hCRTAM-Fc, but not the native CRTAM. Thus, in this study, an exposed disordered epitope in the Ig-like V domain of CRTAM was identified as a potential site for therapeutic antibodies.

References
1.
Le Gall T, Romero P, Cortese M, Uversky V, Dunker A . Intrinsic disorder in the Protein Data Bank. J Biomol Struct Dyn. 2007; 24(4):325-42. DOI: 10.1080/07391102.2007.10507123. View

2.
Adda C, MacRaild C, Reiling L, Wycherley K, Boyle M, Kienzle V . Antigenic characterization of an intrinsically unstructured protein, Plasmodium falciparum merozoite surface protein 2. Infect Immun. 2012; 80(12):4177-85. PMC: 3497424. DOI: 10.1128/IAI.00665-12. View

3.
Dale C, Liu X, De Rose R, Purcell D, Anderson J, Xu Y . Chimeric human papilloma virus-simian/human immunodeficiency virus virus-like-particle vaccines: immunogenicity and protective efficacy in macaques. Virology. 2002; 301(1):176-87. DOI: 10.1006/viro.2002.1589. View

4.
Thrane S, Janitzek C, Agerbaek M, Ditlev S, Resende M, Nielsen M . A Novel Virus-Like Particle Based Vaccine Platform Displaying the Placental Malaria Antigen VAR2CSA. PLoS One. 2015; 10(11):e0143071. PMC: 4657905. DOI: 10.1371/journal.pone.0143071. View

5.
Lopez C, Sethi A, Goldstein B, Wilson B, Gnanakaran S . Membrane-mediated regulation of the intrinsically disordered CD3ϵ cytoplasmic tail of the TCR. Biophys J. 2015; 108(10):2481-2491. PMC: 4457001. DOI: 10.1016/j.bpj.2015.03.059. View